AIM ImmunoTech Inc. (AIM)
NYSEAMERICAN: AIM · Real-Time Price · USD
0.312
-0.043 (-12.18%)
Jun 26, 2026, 4:00 PM EDT - Market closed
AIM ImmunoTech Employees
As of December 31, 2025, AIM ImmunoTech had 21 total employees, including 19 full-time and 2 part-time employees. The number of employees decreased by 2 or -8.70% compared to the previous year.
Employees
21
Change (1Y)
-2
Growth (1Y)
-8.70%
Revenue / Employee
$4,476
Profits / Employee
-$632,190
Market Cap
6.89M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| HCW Biologics | 35 |
| Bolt Biotherapeutics | 23 |
| Imunon | 20 |
| MetaVia | 8 |
| Immuron | 7 |
| Cadrenal Therapeutics | 5 |
| Creative Medical Technology Holdings | 4 |
| Addex Therapeutics | 3 |
AIM News
- 1 day ago - AIM ImmunoTech Proxy statement: Proxy filing - Filings
- 2 days ago - AIM ImmunoTech Accelerates Toward Potential Pivotal Pancreatic Cancer Program as Ampligen Continues to Advance Through Key Clinical Milestones - GlobeNewsWire
- 3 days ago - AIM Sports Group's National SoCal Cup ‘The Showcase' Event Serves Up a Weekend of New Experiences - Business Wire
- 4 days ago - AIM ImmunoTech to Present in the Webull Corporate Connect Webinar Series - GlobeNewsWire
- 8 days ago - AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer - GlobeNewsWire
- 8 days ago - AIM ImmunoTech Registration statement: Registration filing - Filings
- 9 days ago - AIM Talks China 2026 Convenes in Guangzhou, Advancing Strategic Partnerships and Cross Border Investment Across the Greater Bay Area - GlobeNewsWire
- 11 days ago - AIM ImmunoTech Regains NYSE American Compliance, Company Resolves Stockholder Equity Deficiency - GlobeNewsWire